CompletedNot Applicable

CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial

China29 participantsStarted 2018-08-24

Plain-language summary

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with histologically confirmed primary invasive breast adenocarcinoma, anatomic stage T2-4N0-3M0 or T1N1-3M0 before neoadjuvant chemotherapy * ECOG 0-1 * Adequate organ function * Consent to undergo CTC analysis in vivo Exclusion Criteria: * Pregnant or breastfeeding patients * Metastatic or recurrent patients * Uncontrollable infection

What they're measuring

Predictive value of CTC in ypT0 ypN0

Timeframe: Change from pre-chemotherapy to 22-28(±7) days after first dose of neoadjuvant chemotherapy

Trial details

NCT IDNCT03732339

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-03-11

View on ClinicalTrials.gov More Locally Advanced Breast Cancer trials